List of Lexette drug patents

Lexette is owned by Mayne Pharma.

Lexette contains Halobetasol Propionate.

Lexette has a total of 3 drug patents out of which 0 drug patents have expired.

Lexette was authorised for market use on 24 May, 2018.

Lexette is available in aerosol, foam;topical dosage forms.

Lexette can be used as for the topical treatment of plaque psoriasis in patients 18 years of age and older.

The generics of Lexette are possible to be released after 30 May, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof
Nov, 2036

(13 years from now)

US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof
Nov, 2036

(13 years from now)

US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof
May, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's patent expiration?
More Information on Dosage

LEXETTE family patents

8

United States

2

Singapore

2

Japan

2

Brazil

2

Philippines

IB

2

IB

EA

2

EA

2

Canada

2

Mexico

2

Australia

2

Korea, Republic of

2

China

2

European Union

1

Malaysia

1

Spain

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in